Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA Seeks US FDA Rationale For Rx Drug Advertising Studies

Executive Summary

Trade association says research projects are often unnecessary, questions studies of low-internet users and how disclosures about a product affect viewer perceptions.

You may also be interested in...



PhRMA Criticizes 'Exponential Pace' Of FDA Rx Drug Advertising Studies

US FDA responds to comments on proposed study of product disclosures and study of amount and location of risk information.

Rx Drug Ads: New US FDA Studies Target Accelerated Approval Information

Upcoming research projects will look at presentation of FDA approval status, timing of disease awareness ads, and healthcare professional views.

Rx Promotion Citations By US FDA Plummet; UCLA Webpage Elicits Final Letter Of 2017

Last year's record low five letters came as FDA launched flurry of studies on DTC, professional ads; 'Bad Ad' complaints totaled more than 100.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel